FI105919B - Förfarande för framställning av farmaceutiskt godtagbara syra-additionssalter av 2-(1-pyrrolidinyl)etylestern av (+)-5-bensoyl-2,3-dihydro-1H-pyrrolizin-1-karboxylsyra - Google Patents
Förfarande för framställning av farmaceutiskt godtagbara syra-additionssalter av 2-(1-pyrrolidinyl)etylestern av (+)-5-bensoyl-2,3-dihydro-1H-pyrrolizin-1-karboxylsyra Download PDFInfo
- Publication number
- FI105919B FI105919B FI940171A FI940171A FI105919B FI 105919 B FI105919 B FI 105919B FI 940171 A FI940171 A FI 940171A FI 940171 A FI940171 A FI 940171A FI 105919 B FI105919 B FI 105919B
- Authority
- FI
- Finland
- Prior art keywords
- ethyl ester
- pyrrolidinyl
- ketorolac
- dihydro
- benzoyl
- Prior art date
Links
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 150000003839 salts Chemical class 0.000 title claims abstract description 20
- 239000002253 acid Substances 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 4
- -1 2- (1-pyrrolidinyl) ethyl Chemical group 0.000 title abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 125000004494 ethyl ester group Chemical group 0.000 claims abstract description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 5
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 claims description 2
- 229960003750 ethyl chloride Drugs 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 150000003891 oxalate salts Chemical class 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 21
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract description 13
- 208000025865 Ulcer Diseases 0.000 abstract description 12
- 230000000202 analgesic effect Effects 0.000 abstract description 10
- 230000036269 ulceration Effects 0.000 abstract description 8
- 239000000730 antalgic agent Substances 0.000 abstract description 4
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000001754 anti-pyretic effect Effects 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- YMDNODNLFSHHCV-UHFFFAOYSA-N 2-chloro-n,n-diethylethanamine Chemical compound CCN(CC)CCCl YMDNODNLFSHHCV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- RMGFLMXDCGQKPS-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine Chemical group ClCCN1CCCC1 RMGFLMXDCGQKPS-UHFFFAOYSA-N 0.000 description 1
- FSNGFFWICFYWQC-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine;hydron;chloride Chemical compound Cl.ClCCN1CCCC1 FSNGFFWICFYWQC-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (2)
1. Förfarande för framställning av farmaceutiskt godtagbara syraadditionssalter av 2-(1-pyrrolidin)-etyl-' 5 estern av (±)-5-bensoyl-2,3-dihydro-lH-pyrrolizin-l-kar- boxylsyra med formeln (I) N O N''"N (I)
10 Qfi/s ^ kännetecknat av att (±)-5-bensoyl-2,3-15 dihydro-lH-pyrrolizin-l-karboxylsyra alkyleras med 2-(l-pyrrolidin)etylklorid eller ett sait av denna eller med Iti» * 1 ett ekvivalent alkylerande reagens och motsvarande syra • » • 1” tillsätts för bildning av önskat additionssalt. 1'·: 2. Förfarande enligt patentkrav 1, kanne- 20 tecknat av att man framställer oxalatsaltet av fö- • j· reningen med formeln (I) . • · · III • 1 1 * · • · • Il ·»· • « * • · 1 • f · III • · · • · * · · • • · f · · • · 1 • I · » · · · « 9 « ·
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4300697A DE4300697C1 (de) | 1993-01-13 | 1993-01-13 | Keterolac-Derivat mit wesentlich geringerer gastrointestinaler Reizung und Ulzeration |
| DE4300697 | 1993-01-13 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI940171A0 FI940171A0 (sv) | 1994-01-13 |
| FI940171A FI940171A (sv) | 1994-07-14 |
| FI105919B true FI105919B (sv) | 2000-10-31 |
Family
ID=6478109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI940171A FI105919B (sv) | 1993-01-13 | 1994-01-13 | Förfarande för framställning av farmaceutiskt godtagbara syra-additionssalter av 2-(1-pyrrolidinyl)etylestern av (+)-5-bensoyl-2,3-dihydro-1H-pyrrolizin-1-karboxylsyra |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US5508301A (sv) |
| EP (1) | EP0606657B1 (sv) |
| JP (1) | JPH06316577A (sv) |
| KR (1) | KR940018387A (sv) |
| AT (1) | ATE144775T1 (sv) |
| CA (1) | CA2113226A1 (sv) |
| DE (2) | DE4300697C1 (sv) |
| DK (1) | DK0606657T3 (sv) |
| ES (1) | ES2094454T3 (sv) |
| FI (1) | FI105919B (sv) |
| GR (1) | GR3021717T3 (sv) |
| HU (1) | HU216841B (sv) |
| NO (1) | NO301013B1 (sv) |
| ZA (1) | ZA94183B (sv) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020050188A (ko) * | 2002-03-19 | 2002-06-26 | 에코바이오젠주식회사 | 경피흡수제로서의 용도를 위해 지용성이 부가된케토로락의 에스테르 유도체 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4089969A (en) * | 1976-07-14 | 1978-05-16 | Syntex (U.S.A.) Inc. | 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof |
| JPS539788A (en) * | 1976-07-14 | 1978-01-28 | Syntex Inc | 55aloyll1*22dihydroo3hh pyroro *1*22a* pyroll11 carboxylic acid derivative |
| ZA882957B (en) * | 1987-04-27 | 1989-12-27 | Syntex Pharma Int | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal anti-inflammatory drugs |
| DK0519983T3 (da) * | 1990-03-16 | 1996-10-14 | Procter & Gamble | Anvendelse af ketorolac til behandling af periodontal sygdom |
-
1993
- 1993-01-13 DE DE4300697A patent/DE4300697C1/de not_active Expired - Fee Related
- 1993-12-30 DK DK93121130.4T patent/DK0606657T3/da active
- 1993-12-30 AT AT93121130T patent/ATE144775T1/de active
- 1993-12-30 EP EP93121130A patent/EP0606657B1/de not_active Expired - Lifetime
- 1993-12-30 DE DE59304359T patent/DE59304359D1/de not_active Expired - Fee Related
- 1993-12-30 ES ES93121130T patent/ES2094454T3/es not_active Expired - Lifetime
-
1994
- 1994-01-03 HU HU9400006A patent/HU216841B/hu not_active IP Right Cessation
- 1994-01-07 US US08/178,541 patent/US5508301A/en not_active Expired - Fee Related
- 1994-01-11 CA CA002113226A patent/CA2113226A1/en not_active Abandoned
- 1994-01-12 ZA ZA94183A patent/ZA94183B/xx unknown
- 1994-01-12 JP JP6013935A patent/JPH06316577A/ja active Pending
- 1994-01-12 KR KR1019940000417A patent/KR940018387A/ko not_active Application Discontinuation
- 1994-01-12 NO NO940109A patent/NO301013B1/no unknown
- 1994-01-13 FI FI940171A patent/FI105919B/sv active
-
1995
- 1995-06-06 US US08/468,648 patent/US5574170A/en not_active Expired - Fee Related
-
1996
- 1996-11-20 GR GR960403112T patent/GR3021717T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2113226A1 (en) | 1994-07-14 |
| GR3021717T3 (en) | 1997-02-28 |
| DK0606657T3 (da) | 1997-04-14 |
| DE4300697C1 (de) | 1994-05-19 |
| FI940171A (sv) | 1994-07-14 |
| NO301013B1 (no) | 1997-09-01 |
| ES2094454T3 (es) | 1997-01-16 |
| HUT70410A (en) | 1995-10-30 |
| EP0606657A1 (de) | 1994-07-20 |
| DE59304359D1 (de) | 1996-12-05 |
| HU9400006D0 (en) | 1994-05-30 |
| KR940018387A (ko) | 1994-08-16 |
| US5508301A (en) | 1996-04-16 |
| ATE144775T1 (de) | 1996-11-15 |
| US5574170A (en) | 1996-11-12 |
| HU216841B (hu) | 1999-09-28 |
| NO940109D0 (no) | 1994-01-12 |
| JPH06316577A (ja) | 1994-11-15 |
| NO940109L (no) | 1994-07-14 |
| ZA94183B (en) | 1994-08-18 |
| EP0606657B1 (de) | 1996-10-30 |
| FI940171A0 (sv) | 1994-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3752826A (en) | Aroyl substituted pyrroles | |
| US4400394A (en) | Benzylidene derivatives | |
| FI108637B (sv) | Förfarande för framställning av som läkemedel användbar trometaminsalter av (+)-(S)-2-(3-benzoylfenyl)propansyra | |
| US4501727A (en) | Therapeutic agent | |
| US4556671A (en) | Pharmaceutical formulations | |
| FI105919B (sv) | Förfarande för framställning av farmaceutiskt godtagbara syra-additionssalter av 2-(1-pyrrolidinyl)etylestern av (+)-5-bensoyl-2,3-dihydro-1H-pyrrolizin-1-karboxylsyra | |
| WO1989003682A1 (en) | Benzothiazine dioxide derivatives | |
| EP0077720B1 (fr) | Dérivés de biphényl alcoyl carboxylates, leur procédé de préparation et leur utilisation comme médicaments | |
| US4285935A (en) | Dehydropeptide compounds, their production and their medical use | |
| US5451606A (en) | Anthraquinone compounds useful to treat osteoarticular conditions, pharmaceutical compositions and method of treatment | |
| EP0079639B1 (en) | A new anti-inflammatory drug | |
| JP2528343B2 (ja) | 新規なプロリナ―ル誘導体 | |
| CH628014A5 (en) | Gamma-aryl-gamma-oxoisovaleric acids having antiphlogistic and antalgic properties | |
| JPH05331129A (ja) | カフェー酸誘導体及びそれを含む医薬組成物 | |
| US4532249A (en) | Derivatives of p-acylaminophenol having a therapeutic action, and compositions having a therapeutic action containing said derivatives as pharmacologically active ingredients | |
| KR970011456B1 (ko) | d-2-(6-메톡시-2-나프틸)-프로피온산의 광학활성 유도체와 이것을 함유한 약제학적 조성물 | |
| US4122199A (en) | Amides of pyrrolidinoethylamine which can be used in treatment of coughs | |
| CH641775A5 (fr) | N-(1-methyl 2-pyrrolidinyl methyl) 2,3-dimethoxy 5-methylsulfamoyl benzamide et ses derives, son procede de preparation et composition le renferment. | |
| BG108065A (bg) | Нова бензоилгуанидинова сол | |
| HU210203A9 (hu) | Lényegesen kevesebb gasztrointesztinális irritációt és fekélyképződést okozó ketorolak-származékok Az átmeneti oltalom az 1-2.. igénypontra vonatkozik. | |
| US3917842A (en) | Thiopyranopyrrolylsalicylic acids and derivatives thereof | |
| US3118906A (en) | 3-substituted-3-pyrrolidinols | |
| KR100246821B1 (ko) | 비스테로이드성 소염진통제인 티아펜타렌카르복실산 유도체 | |
| FR2548183A1 (fr) | Diphenylazomethines portant un radical imidazolyle, leur preparation et leur application en therapeutique | |
| JPS6051111A (ja) | 抗脂血剤 |